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ABSTRACT 
 
 
Background: Upper gastrointestinal bleeding (UGIT) is a common presentation to hospital and 
can result in a significant morbidity, mortality and hospital costs. Consensus guidelines are 
present from various international expert bodies regarding the management of these patients 
and compliance with these guidelines is variable and is dependent on rigorous implementation 
and continuous audits. 
 
Aim: The primary aim of this study is to evaluate complaints to three aspects of management 
of UGITB (time of endoscopy ,use of dual endotherapy and haemoglubin trigger for 
transfusion)  at Acute Care Surgery Unit, at Groote Schuur Hospital.   
Methods: This is a comparative study between a retrospective control group and a prospective 
cohort post implementation of a quality improvement program (QIP). 
 
 
Results: This study included 109 patients, 51 in the control and 58 in the QIP group. The two 
groups were statistically comparable in terms of demographics, clinical presentation, referral 
pattern and endoscopy finding. 
 
 
Over 80% in both groups had their endoscopy within 24 hours (Control 83.7%, QIP 81.6%). Time 
to endoscopy was not statistically significantly different between the Control and QIP groups 
for low and high-risk patients ((suspected varices or Modified Glasgow-Blatchford Score (MBS) 
>10)). However, when both groups are combined, patients with an MBS of >10 or more had a 
statistically shorter ‘Time to scope’ by 8 hours than those with a score < 10 (p=0.02). 
 
 
 
 
 
 
III 
 In the presence of blood in the upper GIT on OGD, the practice of dual endotherapy 
improved post-implementation (p=0.023). Out of 12 bleeding ulcers (Forrest IA, IB, and IIA, 
IIB) 5 (41.6%) had dual therapy in the Control group versus 10 out of 14 (71%) in QIP group. 
 
Blood transfusion was performed in (Control 72.5%, QIP 65.5%). The mean Haemoglobin in 
stable patients who were transfused was statistically different between Control 6.3 (SD2) and 
QIP 5.7 (SD1.69) (p=0.04). The number of transfusions for HB above 7 was 12 (23.5%) 
(Control) to 6 (10.3%) (QIP) (p=0.047). Thirty-day mortality rate was 9.8% (Control) and 10.3% 
(QIP). The QIP did not affect re-bleeding, surgery and mortality. 
 
Conclusion: This QIP was successful in terms of using dual endotherapy for high-risk ulcers 
and decreasing the rate of inappropriate blood transfusions. The time to endoscopy did not 
significantly change between the two groups; however, the 24h endoscopy rate was over 
80%, which is better than high-income countries registry audits. 
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1. Literature review 
 
 
1.1 Introduction 
 
 
Upper gastrointestinal bleed (UGIT) is a common emergency presentation that can lead to 
hemodynamic compromise and mortality. Anatomically, frank blood loss proximal to the 
ligament of treitz is considered as an UGIT bleed.
1
 The incidence is reported as 48 to 172 per 
100000 in first world literature. 
2 3 4 5
 Various international consensus guidelines are available 
to aid triage and management. The mortality rate has decreased significantly after the 1990s. 
This is attributed to the availability of proton pump inhibitors and advances in endoscopic 
management. However, the decrease in mortality has plateaued in most countries, currently 
reported between 2 to 14%. 
3 6 4 7
 It is hoped that strict implementation of consensus 
guidelines can further improve mortality rates. 
 
1.2 Incidence 
 
 
The incidence of UGIT bleed in South Africa is not known. Internationally the figures vary from 
48 to 172 per 100000 patients.
2 7 5
 In the United Kingdom this translates to 50 000 to 70 000 
hospital admissions yearly with about 4000 deaths.
7
 A Japanese population study showed 
that death related to peptic ulcer disease has not declined after 1990 despite advances in 
treatment.
8 
 
1.3 Etiology and risk factors 
 
 
UGIT bleed can be broadly categorized into variceal bleeding (VB) and non-variceal bleeding 
(NVB). NVB predominates in 80 to 90% of cases. Peptic ulcer disease (PUD) accounts for 20 to 
50% of NVB. Helicobacter pylori infection and the use of non-steroidal anti-inflammatory drugs 
(NSAIDs) have strongly been associated with PUD. A meta-analysis by Huang et al showed that 
the relative risk of a bleeding ulcer with H. Pylori was 1.79, with NSAID use was 4.85 and 
combined was 6.13.
9
 Similarly, in a study by Papatheodoridis et al, H. pylori were detected 
more in cases of bleeding than controls and double the risk of UGIT bleeding amongst NSAIDs 
 
1 
users.
10
 The incidence of PUD ulcer bleed has decreased in younger patients and increased in 
the older patient population group. This is most likely due to the increasing use of low dose 
aspirin as prophylaxis in the older population. The number of older patients with bleeding 
PUD increased from 9.2% in the 1970s to 27.8% in the 1990s.
8 
 
Portal hypertension secondary to cirrhosis is the leading cause of variceal bleeding. Alcoholic 
cirrhosis is the dominant etiology for portal hypertension.
11 12 13
 The cumulative incidence of 
varices in cirrhotic patients at 10 and 20 years were 44% and 53% respectively.
14 
 
Table 1: Causes of Upper Gastrointestinal bleeding  
 Causes Percentage (%) 
   
 Common Causes  
 PUD 20-50 
 Mallory-Weiss tear 20-25 
 Sever erosive gastroduodenitid/ esophagitis 10-15 
 Esophageal varices  
 Portal hypertensive gastropathy  
 Angiodysplasia (vascular ectasia) 5 
 Mass lesions (polyps/cancer) 1-2 
 No lesion identified 10-15 
 
Less common causes 
 
Dieulafoy’s lesion 
 
Gastric antral vascular ectasia 
 
Hemobilia 
 
Hemosuccus pancreaticus 
 
Aortoenteric fistula 
 
Cameron lesions 
 
Ectopic varices 
 
Iatrogenic bleeding after endoscopic intervention   
*only known percentage prevalence is shown in the table 
 
 
 
 
 
 
 
 
 
 
2 
1.4 Clinical picture 
 
 
Upper GI bleeding can present with a wide variety of signs and symptoms depending on the 
speed of the bleed. The most indolent form may present with anemia with its myriad of 
symptoms like fatigue, dizziness, and pallor. The acute form present with haematemesis 
(vomiting of blood, which may be bright red or has an appearance of ground coffee) with or 
without melena (passage of dark tarry stools). Patients with rapid blood loss can present with 
hemodynamic shock and require urgent attention and intervention to prevent mortality. Up to 
10% of upper GI bleeding patients have hematochezia (passage of fresh blood in the feces), and 
can present with signs and symptoms of hypovolemic shock.
15 
 
Re-bleeding in prospective trials is often defined as evidence of fresh bleeding with 
hypovolemic shock or a decrease in Hb of  2g/dl over 24-hours, with confirmation of recurrent 
bleeding by endoscopy or surgery.
16
 This is especially high in variceal bleeding (25–29%) and 
peptic ulcer bleeding (20–22%). 
5 
 
1.5 Resuscitation 
 
 
This literature review will focus on certain parts of management only. For the purpose of the 
study, we decided to implement certain aspects of management that we think we are poor 
at and could make a difference in outcomes. These aspects will be discussed in this literature 
review more thoroughly. 
 
Initial management should focus on resuscitation corresponding to a hemodynamic status. 
This is done using the ATLS principles. Volume restoration initially is done using a crystalloid 
or colloid. In patients known with or suspected to have liver cirrhosis, the use of Saline solution 
should be avoided or limited. The lack of aldosterone metabolism by failing liver results in the 
retention of sodium and hence water. The excess fluid can result in worsening ascites, which 
increases the risk of spontaneous bacterial peritonitis. Sepsis will result in liver 
decompensation, increasing portal pressures and worsening coagulopathy. Re-bleeding as a 
result of decompensation has a mortality rate of above 70%.
12 17 
 
 
3 
1.6 Blood transfusion 
 
 
Blood and blood products are used either during resuscitation or to correct anemia in stable 
patients. Hb thresholds for transfusion in UGIB remain controversial. The threshold 
recommended in non-variceal bleeding (NVB) is a Hb level of <7 g/dL and for VB <8 g/dL.
18 19
 
In patients with ischemic heart disease (IHD) or risk, the Hb target should be 9g/dL. A RCT 
published in the New England Journal of Medicine in 2013 shows that restrictive transfusion 
strategy (Hb < 7g/dL) had better mortality outcomes. The subgroup that performed best was 
patients with variceal bleeding with Child-Pugh score A and B. Re-bleeding and adverse effects 
were higher in the liberal strategy group. This transfusion trigger of Hb 7, however, should only 
be applied in the correct clinical setting i.e. out of resuscitation scenario and stable patients 
without IHD. 
 
1.7 Risk stratification assessment: 
 
 
Risk stratification scores are used to triage patients after resuscitation, which helps with 
identifying the high risk group that needs earlier intervention and closer monitoring. There 
are pre and post endoscopy scores. All consensus guidelines recommend using scores to 
stratify patients into low and high risk. However, registry data worldwide shows poor use of 
these scores. 
20 
 
Initial risk stratification is important in determining the timing of endoscopy. The Modified 
Blatchford score and Rockall pre-endoscopy score can be used to identify patients who 
require endoscopic intervention earlier. The full Rockall score includes endoscopic findings 
and is used to predict re-bleeding and mortality.
4 2 
 
 
 
 
MBS of 0 and 1 has a less than 1% chance of needing intervention and these patients can 
be considered for outpatient management. Patients with MBS score of 10 or more are likely 
to need urgent intervention compared to patients with lower scores. 
 
 
 
 
4 
 The full Rockall score can be done post endoscopy to identify patients at risk of re-bleeding and 
higher mortality. A score of less than 2 has zero mortality. A score of 3 to 4 implies medium risk 
with re-bleeding rate of up to 14% and mortality of up to 5.3%. A score of 5 and above implies 
high risk. Patients with the highest score of 7 have a re-bleeding rate of 41.8% and mortality of 
41%. 4 
A new score, AIMS 65 score has been validated as another pre-endoscopic risk assessment tool. 
It consists of clinical and biochemical variables like albumin (< 30 g/L), INR > 1.5, mental state 
alteration, Systolic BP < 90 and age > 65. It seems superior to pre-endoscopic Rockall and 
Blatchford scores in predicting inpatient mortality, length of stay, and need for intensive care 
admission.21 A low score of 1 or less has a mortality rate of 3.2% and the highest score of 5 has 
a mortality rate of 24.5%. It was not possible to do this score with our study as not all patients 
have an albumin and INR checked in our cost saving system. We also decided to use the 
Modified Blatchford score as it requires less data and has been validated to be equally efficient 
as the full or Glasgow – Blatchford score. 
For patients with liver cirrhosis we also used the Child Pugh score. Please see Addendum for all 
above mentioned scores. (With the tables please put MBS, Rockall pre and post, and child Pugh 
score). 
 
1.8 Pharmacological therapy 
 
A) Proton Pump Inhibitors 
Acid suppressants allow the gastric pH to rise resulting in a more favorable condition for clot 
formation and stabilization. Proton pump inhibitors (PPIs) are superior to H2 Antagonists and 
placebo for down staging lesions with a high stigma of bleeding and therefore less endoscopic 
intervention is necessary. However, this does not translate to improved survival, less surgery 
or less re-bleeding when given pre-endoscopy. A 2010 Cochrane review, 22 23 and other 
studies  like the meta-analysis by Andriulli et al amongst others supports this finding.16 24 25 
 
 
                                                                                              5 
  
2
3 
 In the South African context where endoscopy is not readily available at all facilities or 
after hours even in bigger centers, the commencement of IV PPI is beneficial. 
 
The best route and dosage of PPI is not clear. NICE recommends routine administration of PPI 
for NV UGIB and signs of recent hemorrhage shown at endoscopy but does not recommend the 
best route, dosage or duration.
7
 In western countries it is standard practice to give high dose 
PPI followed by an infusion for 48 to 72 hours for patients with lesions with high stigmata of 
bleeding (Forrest IA, IB, IIA, and IIB). There are no good head to head trials comparing high 
dose to low dose or to oral treatment. However, in one study low dose IV PPI did reduce re-
bleeding rates but didn’t impact mortality or surgery need.
26
 When IV treatment is not 
available, oral PPIs should be given at four times higher dose.
27 
 
B) Tranexamic acid 
 
The use of Tranexamic acid (TXA), an anti-fibrinolytic drug, in UGIT bleed has been found to be 
beneficial. A meta-analysis of RCTs in patients with UGIT bleed showed a 39% reduction in 
mortality in patients that were given TXA than in the control group.
28
 This is not routine 
practice in our center or found to be in the large registry data published internationally. 
 
C) Vasopressors 
 
There is good evidence to support the use of vasoactive drugs to lower portal pressures for 
patients with variceal bleeding. Terlipressin (a synthetic vasopressin analogue) in placebo 
controlled trials has shown to increase the success of endoscopic management and decrease 
 
mortality.
29
 Somatostatin or its analogue Octreotide have shown similar efficacy to 
terlipressin in a meta-analysis.
30 31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
D) Antibiotics 
 
Antibiotic prophylaxes for gram- negative organisms has been shown to improve survival after 
variceal bleeding. A 2010 review summarised that prophylactic antibiotic use decreased 
infection and mortality rates.
32 
 
1.9 Endoscopic management 
 
A) Early diagnostic endoscopy 
 
Endoscopy remains an essential tool for the assessment and treatment of UGIT bleeding. 
Endoscopy done within 24 hours of admission is considered to be early. Most guidelines 
currently advocate that patients who are hemodynamically stable and have no signs of ongoing 
bleeding after initial resuscitation should have an endoscopy within 24 hours. 
7 18
 Large 
registry analysis shows variable adherence to early endoscopic guidelines. In the Canadian 
RUGBE cohort, 76% of endoscopy was performed under 24 hours from admission with a mean 
of 23 hours.
3
 In the United Kingdom only 50% had endoscopy within 24 hours.
33
 Comparing 
very early (<12 hours) to late early (>12 hours) endoscopy, a meta-analysis found no significant 
reduction in re-bleeding, surgery or mortality with early (<12 hours) endoscopy compared with 
 
late (>12 hours) endoscopy.  
 
 
. 
 
 
 
 
Moreover, it was found that urgent endoscopy (0 to 8 hours) versus early endoscopy (6 or8 to 
24 hours), did not show difference in clinical outcomes. 
Early endoscopy (<24 hours) decreases hospital stay, is cost effective and safe in terms of 
discharging appropriately once endoscopy is done compared to endoscopy after 24 hours. 
Very early endoscopy (<12 hours) is recommended in certain risk groups like the suspected 
variceal bleed or NVB with high MBS (>10). VB is likely to recur and hence early endoscopy and 
treatment prevents re-bleeding and mortality. A high MBS (>10) indicates severe bleeding, 
these patients are likely to have ongoing bleeding or are at high risk of re-bleeding. 
 
                                                                                           7 
 
 
  34 35 36 37 
36 38 39 
B) Second look endoscopy 
 
Current data does not recommend second look endoscopy. In the era of dual endotherapy and use 
of high dose PPI for high-risk lesions there is no benefit from a second look endoscopy.
40 41 
27 This should be reserved for patients showing signs of ongoing bleeding.18 
 
C) Therapeutic endoscopy 
 
 
The modified Forrest classification is used to stratify bleeding ulcers which can aid treatment 
decision and risk stratification for re-bleeding and mortality. (addendum ,Forrest classification) 
All actively bleeding or ulcers with stigmata of recent bleed (Forrest I and 2A) need endoscopic 
intervention. 
4 
 
D) Therapeutic endoscopy for non-variceal bleeding 
 
 
Various modalities of endotherapy can aid hemostasis, including injection, application 
of mechanical clips, and thermal therapy. 
 
1)  Injection therapy: 
 
The injection of adrenalin in non-variceal bleeding is based on the principle of vasoconstrictive 
action and vascular tamponade, fibrinoid degeneration of the arterial wall and thrombus 
formation. In a large meta-analysis of 1,673 patients, additional therapy to adrenalin injection 
reduced the re-bleeding rate from 18.4% to 10.6%, and mortality from 5.1% to 2.6%.
42 
 
2)  Mechanical therapy: 
 
Endoclips or hemoclips are used for hemostasis for bleeding vessels. A meta-analysis 
showed clip application was shown is better than injection therapy in achieving definitive 
hemostasis (86.5% vs 75.4%).
43 
 
 
 
 
 
 
 
 
 
 
 
 
8 
3)  Thermal therapy: 
 
Two types of thermal hemostasis are available: contact and non-contact. With contact thermal 
therapy, the vessel is sealed by a combination of mechanical pressure and heat, causing 
coagulation and thrombosis. Non-contact thermal therapy includes argon plasma coagulation 
(APC), where ionized argon gas delivers a monopolar electrical current coagulating tissues.
44 
 
E) Therapeutic endoscopy for variceal bleeding 
 
Variceal bleeding can be controlled with various methods including injection sclerotherapy 
or tissue adhesive injection, band ligation and Sengstaken tube insertion. 
 
1)  Injection therapy: 
 
Sclerosant agents (tetrcyadel sodium, sodium morrhuate, and ethanolamine oleate) are 
injected in or next to varices necrosis, fibrosis and obliteration of the varices. Complications 
include severe esophagitis, esophageal stricture formation and oesophageal perforation.
12
 
Tissue adhesives (cyanoacrylate tissue adhesives such as N-butyl-cyanoacrylate (histoacryl), 
isobutyl-2-cyanoacrylate, or 2-octyl cyanoacrylate) are used for gastric varices. In a 
retrospective study, thirty-seven patients underwent cyanoacrylate glue injections. It was found 
that initial hemostasis was achieved in 95%, while early rebleeding occurred in 8% and late 
 
rebleeding occurred in 28% of patients.
45 
 
 
 
 
1) Mechanical therapy: 
 
Band ligation is the recommended endoscopic treatment of oesophageal varices. 
 
Band ligation results in better hemostasis and less mortality compared to sclerotherapy. 
47
 For 
gastric varices glue injection is superior to banding.
48 
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          17 46 26  
2)  Balloon tamponade: 
 
Balloon tamponade is useful when there is a failure of other methods of variceal 
hemostasis. Sengstaken- Blakemore tube achieves hemostasis in 91.5% of cases, with a 
recurrence of bleeding in approximately 50% of cases after balloon deflation. It is a 
temporary method to stabiles patient and used as a bridge to a more definitive procedure. 
49 
 
F) Dual therapy 
 
A meta-analysis of injection therapy versus injection with the second modality showed less re-
bleeding with dual therapy (10.6% versus 18.4%) and less mortality (2.6% versus 5.1%). 
Further studies and a Cochrane review have confirmed that injection therapy on its own is 
inferior to dual therapy. All consensus guidelines currently recommend dual therapy for ulcers 
with high stigmata of bleeding (Forrest I and 2A). 
 
G) Adherent clot 
 
 
There is controversy regarding the management of an adherent clot (Forrest 2b ulcer). The risk 
of re-bleeding varies from 8 to 36% with clot manipulation. Clot irrigation or endoscopic 
manipulation can reveal a higher stigmata lesion underneath in 70% of patients. 
50
Two meta-
analysis of RCTs showed no benefit with endoscopic management versus high dose IV PPI. 
26
 
Another analysis of 4 trials showed less re-bleeding with endoscopic management. A meta-
analysis by Kahi et al showed less re-bleeding and need for surgery, however, this did not 
impact mortality. 
51
 Consensus guidelines recommend either option, endoscopic treatment or 
higher dose IV PPI. 
 
 
1.10 Outcomes and predictors of mortality 
 
Various studies have found certain factors to be associated with increased mortality. The risk 
stratification scores for UGIT bleed factors these predictors to identify patients at risk of 
needing more urgent treatment and patients with  higher mortality risk. Mortality after UGIT 
bleed has been quoted as between 2 and 14% in the literature. 
 
 
 
                                                           
 
                                                 10 
 
  6 2 7 3 52 4 
 The Italian PNED registry showed that advanced age (>80); severe co-morbidities like ASA >3, 
renal failure, liver failure, and advanced malignancy; low Hb (<7g/dL) and failure of endoscopic 
treatment (re-bleeding) were all factors associated with mortality. This registry’s mortality 
rate was 4.5%. 
52 
 
The Canadian RUGBE study had a mortality rate of 5.4%. This is less than previously reported 
and it is attributed to the use of proton pump inhibitors.
3 
 
Rockall et al’s landmark paper notes re-bleeding as a major risk factor for mortality. They noted 
that patients in the middle score group (Rockall 3-4) had a fivefold increase in mortality with re-
bleeding and patients with higher scores (above 5) had a threefold increase in mortality with re-
bleeding. There was zero mortality in the group with scores 2 and less. The overall mortality in 
this paper was 14%. 
 
Levin et al’s study done at our hospital previously showed a mortality rate of 12.8%. 
Re-bleeding and presence of co-morbid disease were found to be significant risk factors 
for mortality. 
53 
 
A new prognosticator score, AIM65 includes low albumin levels (<30g/L), as it has been shown 
to be an independent predictor of mortality.
54 
 
Other risk factors are shock, clinical evidence of bleeding and sepsis. 
 
 
A study by parvez et al in a private tertiary state of the art hospital in India showed a mortality 
rate of 2.6%. They attribute this low rate to expedited endoscopy, availability of critical care 
and early presentation to hospital by the patients.
6 
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1.11 Guideline recommendations and practice 
 
 
International guidelines for the management of UGIT are constantly being refined by senior 
gastroenterologists as evidence from RCT and cohort studies have accrued to provide sound 
evidence on which to base their recommendations. There are various guidelines from 
several countries available like NICE UK and American College of Gastroenterology 
Guidelines for upper GIT bleeding. 
 
The international consensus recommendations on the management of patients with Non 
variceal UGIT bleeding from 2010 contains 11 recommendations in six categories and details 
the criteria and cut-off levels when appropriate. These categories are: Adequate 
resuscitation, prognostic stratification, transfusion triggers, PPI acid suppression, early 
endoscopy and dual endotherapy.
19 
 
 
 
 
Pertinent points of recommendations from the International consensus document in 
relation to our study are :
19 
 
 
 
 
1) Resuscitate appropriately after initial evaluation 
 
2) Use prognostic scales to risk stratify into low and high risk for re-bleeding and mortality 
 
3) Transfuse blood if Hb 7g/dL in stable patients 
 
4) Consider pre-endoscopic proton pump inhibitor (PPI) to downstage lesion 
 
5) Early endoscopy (<24 hours) is recommended 
 
6) Adrenalin injection therapy alone is suboptimal and should be used in conjunction 
with another method 
 
7) Finding a clot in the ulcer bed warrants targeted irrigation to dislodge the clot, with 
appropriate therapy of underlying lesion 
 
8) Adherent clot management is controversial. Endoscopic therapy or intensive PPI 
therapy alone may suffice 
 
 
12 
 9) Clips, thermocoagulation or sclerosant injection can be used in high risk lesions, alone 
or in conjunction with adrenalin injection 
 
10) Routine second look endoscopy is not recommended and reserved for re-bleeding 
 
11) An intravenous bolus with continuous infusion of PPI should be used after successful 
endoscopic therapy of high risk ulcers 
 
 
 
Audits of registries show mostly below average uptake of guidelines. There is definitely a gap 
between what is recommended and what happens in real practice. In the United Kingdom 
there was 47.5% to 66% compliance to endoscopy within 24 hours in baseline audits.
55 56
 
Canadian RUGBE study showed a 76% 24 hour endoscopy rate.
3
 Similarly to the French audit 
57
 
in 2006 showed that 70.9% had injection therapy alone for high-risk bleeding ulcers and 
mirrored our own institutions practice of a 100% monotherapy use for high risk ulcers reported 
by Levin et al between 2004 and 2009.
53 
 
 
 
 
1.12 The GSH perspective 
 
 
The GSH endoscopy service is fragmented and variable. The service is provided by the GI unit 
during office hours, which comprises of surgical gastroenterology, acute care surgery and Medical 
GIT consultants, fellows and registrars. After-hours the unit is not available, and all endoscopy 
must be done in theater. With aging equipment, confusion about who is buying consumables and 
a mixed rotation for endoscopy cover, the care were dependent on the skills and enthusiasm of 
the on-call team. The last few years with acute care surgery being at the forefront of emergency 
cover, they have addressed all the hurdles for after-hour endoscopy. The study was done after 
they ensured equipment availability (it is still not ideal circumstances), adequate supply of 
consumables, availability of Gold probe in theater and change of on-call roster to avoid 
confusion (All after-hours endoscopy now provided by Acute care surgery only). Standard 
management protocols for management of UGIT bleed were drawn up and implemented as part 
of the project. They felt the areas they did poorly were the 
 
13 
 delay to endoscopy after admission and use of adequate dual endotherapy for bleeding 
ulcers. Blood transfusion protocol out of resuscitation was also not standardized. These three 
points are the focus of this quality improvement program. They also aim to audit their 
mortality over this two-year period. 
 
 
 
 
1.13 Conclusion 
 
 
UGIT bleeding is a common emergency admission. The mortality rate has decreased 
significantly with the use of high dose PPI and adequate endotherapy in first world countries. 
Adherence to consensus guidelines remains problematic everywhere. Can mortality rates 
drop even more with strict implementation of these guidelines? Is it possible to adhere to 
these guidelines in a system that has its challenges? 
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2.2 ABSTRACT 
 
 
 
 Background: Upper gastrointestinal bleeding (UGIT) is a common presentation to hospital and 
can result in a significant morbidity, mortality and hospital costs. Consensus guidelines are 
present from various international expert bodies regarding the management of these patients 
and compliance with these guidelines is variable and is dependent on rigorous implementation 
and continuous audits. 
 
Aim: The primary aim of this study is to evaluate complaints to three aspects of management 
of UGITB (time of endoscopy ,use of dual endotherapy and haemoglubin trigger for 
transfusion)  at Acute Care Surgery Unit, at Groote Schuur Hospital.   
Methods: This is a comparative study between a retrospective control group and a prospective 
cohort post implementation of a quality improvement program (QIP). 
 
 
Results: This study included 109 patients, 51 in the control and 58 in the QIP group. The two 
groups were statistically comparable in terms of demographics, clinical presentation, referral 
pattern and endoscopy finding. 
 
 
Over 80% in both groups had their endoscopy within 24 hours (Control 83.7%, QIP 81.6%). Time 
to endoscopy was not statistically significantly different between the Control and QIP groups 
for low and high-risk patients ((suspected varices or Modified Glasgow-Blatchford Score (MBS) 
>10)). However, when both groups are combined, patients with an MBS of >10 or more had a 
statistically shorter ‘Time to scope’ by 8 hours than those with a score < 10 (p=0.02). 
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In the presence of blood in the upper GIT on OGD, the practice of dual endotherapy 
improved post implementation (p=0.023). Out of 12 bleeding ulcers (Forrest IA, IB and IIA, 
IIB) 5 (41.6%) had dual therapy in the Control group versus 10 out of 14 (71%) in QIP group. 
 
Blood transfusion was performed in (Control 72.5%, QIP 65.5%). The mean Haemoglobin in 
stable patients who were transfused was statistically different between Control 6.3 (SD2) and 
QIP 5.7 (SD1.69) (p=0.04). The number of transfusions for HB above 7 was 12 (23.5%) 
(Control) to 6 (10.3%) (QIP) (p=0.047). Thirty day mortality rate was 9.8% (Control) and 10.3% 
(QIP). The QIP did not affect re-bleeding, surgery and mortality. 
 
Conclusion: This QIP was successful in terms of using dual endotherapy for high risk ulcers 
and decreasing the rate of inappropriate blood transfusions. The time to endoscopy did not 
significantly change between the two groups; however the 24h endoscopy rate was over 80%, 
which is better than high income countries registry audits. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Abstract word count 384) 
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2.3 Text of article 
 
 
 
Introduction and background 
 
Upper gastrointestinal (UGIT) bleeding is a common reason for hospital admission that carries 
a significant risk of morbidity and mortality. The reported incidence varies from 48 to 172 per 
100000 in high-income countries.
1 2 3 4
 In the last two decades the mortality rate has 
decreased and currently ranges between 2 and 14%.
5 6 3 7
 The only recent publication from 
South Africa was by Levin et al in 2012. This tertiary care unit study reported a mortality rate of 
12.8% and surgery rate of 7.9% for non-variceal haemorrhage in 227 patients over 6 years.
8 
 
Management has evolved with adjunct therapies and technical refinements in endotherapy 
and has resulted in a variety of consensus guidelines designed to improve the management and 
outcomes of these patients. Various analysis of compliance to these guidelines suggests that 
these are not rigorously implemented.
9 10
 Against this background we wished to examine our 
compliance with regards to our own internationally adapted guidelines, in the management of 
patients with UGIT bleeding, before and after the implementation of a quality improvement 
program, in a tertiary referral unit. 
 
Materials and Methods 
 
 
Retrospective data collected on 51 consecutive patients over a year constituted the control 
group. Data on 58 consecutive patients were collected prospectively in a year, following the 
Quality improvement program (QIP) implementation. This program consisted of dissemination 
of a unit protocol via email, lectures and placement of protocol posters at strategic points. The 
target intervention groups were General surgery and Medical Gastroenterology registrars, 
fellows and, consultants who are involved in the care of UGIT bleeding patients. A customized 
redcap database was developed to collect data. The study protocol was approved by the local 
Human research ethics committee (244/2017) 
 
All patients admitted to acute care surgery, Groote Schuur hospital (GSH) with signs 
and symptoms of UGIT bleeding were included in this study. Patients that demised prior 
to 
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 endoscopy (unconfirmed) or had no blood or cause for UGIT bleeding at endoscopy were 
excluded from this study. GSH is a tertiary referral institution which admits UGIT bleeding from 
its own catchment area and is the referral hospital for three secondary level hospitals that have 
variable ability to provide a 24-hour endoscopy service. GSH provides a 24 hour endoscopy 
service in a dedicated endoscopy unit during working hours (8 am-4 pm weekdays) with after-
hours endoscopy being performed in the operating theatre. Patients who presented with Grade 
 
III shock (SBP < 100, HR >120) were deemed unstable. All patients were risk-stratified using the 
Modified Blatchford Score (MBS), a validated scoring system that incorporates initial clinical 
findings; blood pressure, heart rate, Hb and urea. Post endoscopy Rockall score parameters 
were recorded to identify patients at risk of re-bleeding and death. Child-Pugh score was used 
to assess the severity of liver decompensation in variceal bleeding. The policy is to give a stat 
dose of intravenous proton pump inhibitor (PPI) to high-risk patients at admission and to 
continue as indicated by endoscopy findings. Regards to suspected variceal bleeding, our policy 
is to start Octreotide infusion on admission. 
 
The Quality improvement program focused on aspects of UGIT bleed care we perceived as 
being poorly adhered to at our institution. We compared adherence to the recommendations 
between the two cohorts for: time to endoscopy (within 24 hours from admission for all, and 
<12 hours for suspected variceal haemorrhage and a MBS>10), the use of dual-modality 
endotherapy and blood transfusion related to a haemoglobin trigger of <7g/dL in 
hemodynamically stable patients with no ischemic heart disease. The primary aim of this study 
was to evaluate the compliance of these three parameters as defined in our guidelines, pre and 
post QIP and their comparison with to international data. Secondary aims were to assess if  the 
implementation of QIP affected re-bleeding, surgery and mortality rates. 
 
Results 
 
 
This study included 109 patients, 51 in the control and 58 in the QIP group. The baseline 
characteristics of the two groups are shown in Table 1. The majority of the characteristics were 
similar between the two groups except for aspirin usage which was significantly higher in the 
control group. 
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 The mean age for both groups was 55 years of age. The frequency of referrals from secondary 
level hospitals was similar in the two groups. The reason for referral was unavailability of scope 
adjuncts for adequate dual therapy or banding (Control 76.2%, QIP 75%) and unavailability of 
after-hours endoscopy service (Control 23.8%, QIP 25%). The majority of the patients were 
normotensive on arrival and Grade III shock was present in 20% of both groups. The frequency 
of co-morbidities was equally distributed in both groups. The most common co-morbidities 
were smoking, non-steroidal use and chronic liver disease. Historical evidence of bleeding was 
twice as common for hematemesis as for melena in both groups. However, melena was more 
frequently confirmed on examination than hematemesis. 
 
The MBS prior to endoscopy was 8.6 (SD 4.2) in the Control group and 8.3 (SD 3.1) in QIP 
group. Post endoscopy Rockall score showed a mean of 3.45 for Control and 3.54 for QIP 
groups. There was no statistical difference between the two groups. 
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 Table 1: Comparison of demographic and baseline characteristics for the Control and 
QIP groups 
 
 
VARIABLE  CONTROL QIP P VALUE <0.05 
DEMOGRAPHICS AND REFERRAL PATTERN      
TOTAL   51 58   
AGE  MEAN (RANGE) Mean (SD) 55 (17.1) 55 (15.6)   
MALE  N (%) 31 (60.8) 35 (60.3)   
FEMALE  N (%) 20 (39.2) 22 (37.9)   
REFERRALS: SECONDARY HOSPITAL  N (%) 20 (39.2) 18 (31.0)   
REFERRAL: INPATIENT N (%) 3 (5.9) 10 (17.2)   
EMERGENCY UNIT ADMISSION N (%) 31 (60.8) 39 (67.2)   
AFTER HOURS ADMISSION N (%) 36 (70.5) 34 (58.6)   
ADMISSION CLINICAL PARAMETERS      
SYSTOLIC BLOOD PRESSURE (MMHG) Mean (SD) 121  (26.2) 116 (23.8)   
HEART RATE (BPM) Mean (SD) 98 (16.3) 102 (20.3)   
HEMOGLOBIN (G/DL) Mean (SD) 7.36 (3.06) 7.01 (2.65)   
GRADE II SHOCK N (%) 17 (33.3) 19 (32.7)   
GRADE III SHOCK N (%) 11 (21.5) 13 (22.4)   
UPPER TRACT BLEEDING EVIDENCE      
MALENA CONFIRMED N (%) 25 (49.0) 34 (58.6)   
MALENA HISTORY N (%) 17 (33.3) 18 (31.0)   
HEMATEMESIS CONFIRMED N (%) 3 (5.9) 8 (13.8)   
HEMATEMESIS HISTORY N (%) 31 (60.8) 39 (67.2)   
FRESH BLOOD SEEN ON SCOPE N (%) 6 (11.7) 12 (20.6)   
OLD BLOOD SEEN ON  SCOPE N (%) 16 (31.3) 19 (32.7)   
RISK FACTORS AND CO-MORBIDITIES      
SMOKER N (%) 24 (47.0) 25 (43.1)   
NSAIDS N (%) 18 (35.3) 15 (25.8)   
ASPIRIN PROPHYLAXIS N (%) 11 (21.5) 3 (5.1) 0.04 
     
PREVIOUS UGIT BLEED N (%) 11 (21.5) 16 (27.6)   
WARFARIN  N (%) 2 (3.9) 2 (3.4)   
ISCHEMIC HEART DISEASE N (%) 6 (11.7) 6 (10.3)   
CARDIAC FAILURE N (%) 6 (11.7) 1 (1.7)   
CHRONIC RENAL FAILURE N (%) 3 (5.9) 0(0)   
LIVER DISEASE N (%) 12 (23.5) 16 (27.5)   
RISK STRATIFICATION       
MODIFIED BLATCHFORD SCORE Mean (SD) 8.6 (4.2) 8.3 (3.1)   
 
 
 
 
 
 
 
*only significant p-value in this table 
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ROCKALL SCORE (POST ENDOSCOPY) Mean (SD) 3.45 (1.8) 3.54 (1.6)   
CHILD PUGH SCORE Total N (%) 14 (27.4) 20 (34.5)   
A N (%) 8 (57) 17 (85)   
B N (%) 4 (28.6) 2 (10)   
C N (%) 2 (14) 1 (5)   
  Endoscopy 
 
The majority of oesophago-gastro-duodenoscopy (OGD) was done within office hours in the GI 
Unit’s dedicated endoscopy suites (Control 92%, QIP 87.9%). The rest were done in an 
operating theatre either as it was after hours or due to unstable hemodynamics. 
 
At OGD there was evidence of bleeding in Control 43.1% and QIP 55.1% of patients. Peptic 
ulcers were found most commonly (Control 43.1%, QIP 40.6%), followed by esophageal varices 
(Control 27.4%, QIP 34.5%) (Table 2). Antral or pre-pyloric lesions were found in 68% of ulcers 
in the control group and 47.8% in QIP group. Proton pump inhibitor was given to 35 (68.6%) 
and 33 (56.9%) prior to OGD in Control and QIP groups respectively. One patient in the Control 
group (1.9%) and two in QIP group (3.4%) with proven PUD did not receive PPIs pre or post-
OGD. The two groups were statistically comparable regarding endoscopy findings. (Table 2) 
 
Out of 12 bleeding ulcers (Forrest IA, IB and, IIA, IIB) 5 (41.6%) had dual therapy in the Control 
group versus 10 out of 14 (71%) in QIP group. One patient in the control group underwent a 
negative laparoscopy for suspected perforation. There were no operations performed for 
bleeding in the control group. Three in the QIP group had surgery after two failed attempts at 
endoscopic control using dual therapy. Surgery involved over-sewing of the bleeding vessel 
through an enterotomy and no resections were required. Repeat OGD was done on demand for 
9 (17.6%) patients in the Control group and in 12 (20.6%) patients in QIP group. In the presence 
of blood in the upper GIT on OGD, the practice of dual endotherapy improved post 
implementation (p=0.023). 
 
There were 14 (27.4%) and 21 (36.2%) patients with variceal bleeding in Control and QIP 
groups respectively. All oesophageal varices were managed with endoscopic banding whilst 
gastric varices were injected with Glue (histo-acryl). Varices occupying more than half the 
esophageal lumen were 57% Control and 45.5% QIP groups. All patients on Control arm were 
treated with Octreotide infusion whereas only 18 out of 21 patients (85.7%) in the QIP arm. 
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Table 2: Comparison of endoscopy findings and outcomes by groups 
 
 CONTROL QIP P VALUE <0.05  
ENDOSCOPY FINDINGS      
  N (%) N (%)  
PEPTIC ULCER DISEASE  22 (43.1)  23 (39.6)   
ANTRAL / PRE-PYLORIC  15 (68.1)  11 (47.8)   
DUODENAL  6 (27.2)  11 (47.8)   
INCISURA  2 (9.0)  3 (13.0)   
BODY  0 (0)  2 (8.6)   
OESOPHAGEAL VARICES  14 (27.4)  19 (32.7)   
GASTRIC VARICES  2 (3.9)  2 (3.4)   
MALLORY WEISS  2 (3.9)  2 (3.4)   
VASCULAR MALFORMATION  0 (0)  2 (3.4)   
GASTRITIS  11 (21.5)  10 (17.2)   
OESOPHAGITIS  2 (3.9)  1 (1.7)   
GASTRIC CANCER  2 (3.9)  3 (5.1)   
POLYPS  1 (1.9)  0 (0)   
PUD FORREST CLASSIFI CATION      
FORREST IA  1 (4.5)  3 (13.0)   
FORREST IB  3 (13.6)  6 (26.0)   
FORREST I IA  4 (18.1)  1 (4.3)   
FORREST I IB  4 (18.1)  3 (13.0)   
FORREST I IC  0 (0)  1 (4.3)   
FORREST I I I  10 (45.4)  9 (39.1)   
SECONDARY END POINTS        
FAILED PRIMARY ENDOSCO PY  9 (17.6)  12 (20.6)   
REQUIRED SURGERY  1 (1.9)  3 (5.1)   
30 DAY MORTALITY  5 (9.8)  6 (10.3)   
 
 
 
*some patients had more than one endoscopy finding, therefore will not add up to total PUD. 
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Table 3 details the difference in the comparator guideline parameters between the two groups. The 
QIP had a four hour greater time delay than the control but this was not statistically or clinically 
significant. Over 80% in both groups had their endoscopy within 24 hours (Control 
 
83.7%, QIP 81.6%). Time to endoscopy was not statistically significantly different between the 
Control and QIP groups for low and high risk patients (suspected varices or MBS >10). However 
when both groups are combined, patients with a MBS of >10 or more had a statistically shorter 
‘Time to scope’ by 8 hours than those with a score < 10 (p=0.02). 
 
Blood transfusion was performed in (Control 72.5%, QIP 65.5%) (Table 1). The reason for 
transfusion was for resuscitation in 17.6% (Control) and 13.8% (QIP). The rest were transfused for 
clinical reasons. The mean Haemoglobin in stable patients who were transfused was statistically 
different between Control 6.3 (SD2) and QIP 5.7 (SD1.69) (p=0.04). The number of transfusions 
for HB above 7 was 12 (23.5%) (Control) to 6 (10.3%) (QIP) (p=0.047). 
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Table 3: QIP results 
 
 
 
 
 
QIP Intervention parameters Control  QIP  P-Value QIP success Other audits 
        
Time to endoscopy (hours)  Hours     
Overall mean 
       
17.8 22.9 0.9 No  
Varices mean 
      
14.2  19.1  0.19 No  
MBS > 10 
       
15.2 17.8   No  
       
  Percent     
Endoscopy within 24 hours 
      
83.7 81.6 0.07  Canada 76% 
       UK 69% 
Dual endotherapy Number (Total)     
       
      
With bleeding evidence on scope 5 (25)  14 (28)  0.02 Yes France 29% 
        
Inappropriate Blood transfusion  Percent     
      
Inappropriately transfused 23.5  10.3  0.047 Yes  
        
 
 
 
 
 
 
 
 
 
Morbidity 
 
 
There was one major morbidity in the control group as a patient had a negative laparoscopy 
for a suspected perforation post endoscopy. After dual endoscopic therapy of an Antral high 
risk ulcer, the patient had localized peritonitis with free air seen under the diaphragm on an 
erect chest X-ray. At laparoscopy, there was no contamination of the peritoneal cavity and no 
ulcer visible. This patient recovered without further problems after surgery. 
 
Mortality 
 
There was one death directly related to bleeding in the QIP group. The mortality rate during the 
index admission was 5.9% (Control) and 1.72% (QIP). 
Thirty- day mortality rate was 9.8% (Control) and 10.3% (QIP). This was not statistically different. 
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 Univariate analysis showed that ‘unstable’ arrival hemodynamics (Grade III shock) was the only 
significant factor in determining 30 day mortality there was no statistical significant risks for 
mortality for age, haemoglobin, urea, Blatchford score, Time to endoscopy, endoscopy finding 
and presence of blood in GI tract. 
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Table 4: Univariate analysis for overall 30 days mortality 
 
 
 
 
 
 P-VALUE 
  
Grade III shock 0.009 
Age 
 
0.154 
Admission Hb 
 
0.49 
Admission Urea 
 
0.58 
MBS 
 
0.58 
Bleeding 
 
0.11 
Scope finding 
 
0.09 
Time to endoscopy 
 
 
0.75 
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Discussion 
 
 
Societal and international guidelines for the management of UGIT are constantly being refined 
by senior gastroenterologists as evidence from RCT and cohort studies have accrued to 
provide sound evidence on which to base their recommendations. The international evidence 
based guideline contains 11 recommendations in six categories and details the criteria and cut-
off levels when appropriate. These categories are: Adequate resuscitation, prognostic 
stratification, transfusion triggers, PPI acid suppression, early endoscopy and dual 
endotherapy.
5 
 
This study focused on three key aspects of UGIT bleeding care that we perceived form our 
current clinical practice required attention: Time to endoscopy, Use of dual endotherapy and a 
restrictive blood transfusion strategy for stable patients. These were the three aspects that 
were emphasized during our QIP implementation period. 
 
All guidelines currently recommend early endoscopy (<24 hours) after admission.
9 11 5
 After 
initial resuscitation patients are risk stratified into high risk and low risk groups. Risk 
stratification can be done using one of the validated pre-endoscopy scores like the MBS or 
Rockall pre-endoscopy score. The Modified Blatchford score is a pre-endoscopy tool that 
utilizes admission clinical and laboratory findings (systolic blood pressure, heart rate, Hb and 
urea). This score has been validated with other studies and correctly identifies the low risk 
patients A MBS of 0 and 1 has a less than 1% chance of needing intervention and these patients 
can be considered for outpatient management. Patients with MBS score of 10 or more are likely 
to need urgent intervention compared to patients with lower scores.
1 9
 Patients with no signs 
of active bleeding and low risk should have their OGD within 24 hours of admission. High risk 
patients, MBS  10 and variceal bleeding, should preferably have their endoscopy within 12 
hours. Patients with signs of ongoing bleeding should have an emergency OGD. In the 
literature, comparing very early (<12 hours) to late early (>12 hours) endoscopy, a meta-
analysis found no significant reduction in re-bleeding, surgery or mortality.
12 13 14 15
 Moreover, 
it was found that urgent endoscopy (0 to 8 hours) versus early endoscopy (6 or 8 to 24 
hours),
14
 
16 17
 did not show differences in clinical outcomes.
14 16 
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 Audits of registries show mostly below average uptake of guidelines. In the United Kingdom 
there was a 47.5% to 66% compliance to endoscopy within 24 hours in baseline audits.
9 10
 
Canadian RUGBE study showed a 76% 24 hour endoscopy rate.
2
 With this background our 
finding of a more than 80% 24-hour endoscopy was pleasantly surprising. More than half were 
admitted after hours (Control 70.5%, QIP 58.6%) and despite this our Time to endoscopy was 
adequate. The QIP implementation didn’t affect our within 24-hour endoscopy rate perhaps as 
our capacity to push for early scope is near the  ceiling. The dedicated endoscopy unit is 
efficient and we capitalize on its excellent service during working hours. After hours endoscopy 
is challenging to arrange and also difficult to justify for stable patients as the emergency 
theatre is shared by all surgical disciplines. This also means that when we do have an 
emergency the operating theatre will go out of its way to accommodate us. This study also 
showed that overall patients with higher MBS had a shorter time to endoscopy on average by 8 
hours. This implies that even before the QIP implementation patients were being risk stratified 
and triaged appropriately. The variceal group on average had a 3 hour shorter time to 
endoscopy than the overall group in both cohorts but this was not statistically significant. 
 
Dual endotherapy use (or rather avoiding monotherapy with injection tamponade only) 
decreases the rate of re-bleeding and mortality. A large meta-analysis in 2004 showed that 
adding a second modality to injection tamponade decreased re-bleeding from 18.4% to 10.6% 
and mortality from 5.1% to 2.6%.
18
 Despite this evidence a French audit in 2006 showed that 
70.9% had injection therapy alone for high risk bleeding ulcers and mirrored our own 
institutions practice of a 100% monotherapy use for high risk ulcers reported by Levin et al 
between 2004 and 2009.
19 8
 This QIP improved compliance to dual endotherapy modality. Our 
concurrent improvement in the availability of accessories for dual therapy at the time of the 
QIP most likely contributed to this improvement. The hesitation was with Forrest 2B (adherent 
clot ulcers) where only 25% had dual therapy. The literature on this is also divided between 
removing the clot and addressing the underlying lesion or using high dose IV PPI. This ambiguity 
in the guidelines reflects the lack of endotherapy in this group. A skilled endoscopist with a 
skilled assistant might attempt to tackle these clots as once stirred up to a third of them will 
resume bleeding. 
20 
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 A restrictive blood transfusion strategy is applied to blood transfusion not only for UGIT but for 
several indications across many disciplines. In a patient that does not have ongoing bleeding, 
who is hemodynamically stable and does not have ischemic heart disease the recommended 
Hb trigger for transfusion is < 7g/dl.
21 11
 A RCT in 2013 reported better mortality outcomes 
with this restrictive strategy in UGIT bleeding patients. 
22
 The subgroup that performed best 
was patients with variceal bleeding with Child-Pugh A and B. Re-bleeding and adverse effects 
were higher in the liberal strategy group. This QIP significantly reduced inappropriate over 
transfusions in our study from 23% to 10%. 
 
The QIP failed to improve re-bleeding, surgery or mortality rates. The study is limited by the 
lack of sufficient patient numbers to see an effect on these secondary aims because of their 
relative infrequent occurrence. Our mortality rate of 9.8% and 10.3% resembles other quoted in 
international literature.
3 2 23
 Levin et al’s study done at our institution over 6 years looked at 
high grade bleeding ulcers only and had a mortality of 12.8%.
8
 The mortality rate for equivalent 
Forrest categories Forrest IA to IIB in this much smaller cohort was 3.7% suggesting a trend 
towards improved in-hospital mortality over the past 8 years. 
 
The mean Rockall score was 3.45 and 3.54 in Control and QIP groups respectively. Both were a 
medium risk and in Rockall et al’s study, the re-bleeding rate was 14% and overall mortality 
rate of 5.3% for medium-risk patients. The second look endoscopy rate was 17 and 20% in this 
study, however, not all of these were bleeding at second OGD. The 30-day mortality rate of 
9.8% and 10.3%in this study is higher than found for medium risk group in Rockall et al’s study. 
However, in the subgroup that had re-bleeding the mortality rate was as high as 15% in this 
landmark paper.
3 
 
Presentation with shock was the only significant risk factor associated with mortality in this 
study. The initial hypotension and transient tissue hypoxia prior to resuscitation has far-
reaching complications unfolding a cascade of organ function decompensation. Direct bleed 
related death was minor (one) and the rest of the deaths were due to medical co-morbidity. 
Could these deaths have been prevented by timely hospital presentation or recognition and 
triage in an overburdened community clinic? In centers that do not have endoscopy readily 
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 available or enough emergency blood, the focus is on getting the patient to endoscopy. A 
burdened emergency center with even more burdened ambulance service results in delays 
in transfer and recognition of the hemodynamic decompensation. 
 
Although our aim was not to look at pharmacotherapy directly, this study shows that the 
adherence to PPI for NVB and Octreotide for VB was good with both above 95%. We also did 
not audit a high dose versus low dose or oral PPI. In our context IV PPIs are available but with 
lack of evidence on definite reduction in surgery and mortality rates, we do not have access to 
high dose infusion use post endoscopy for high risk ulcers. The variceal bleeding protocol has 
been well established as we are a referral center. Up to 30% had variceal bleeding in this study. 
All patients received Octreotide and antibiotics. There is currently an ongoing detailed audit 
regarding VB management in our hospital. 
 
The NICE QIP audit in 2012/2013 highlighted the need for educating clinicians on a regular and 
repeated basis to ensure guideline adherence. It is not merely sufficient to have many 
complex guidelines if this does not reach the day to day practice. Quality audits and 
improvements based on these audits together with continuous education of clinicians can 
result in better patient care. Unit protocols with standardized admission forms asking 
pertinent questions like risk stratification and check list of therapy needed can aid clinicians in 
better management of UGIT bleeding. 
 
This study has provided us with benchmarks values for adherences for three key guideline 
recommendation in the management of UGIT. We have shown in this study over a period of 
two years that our compliance with time to endoscopy of less than 24 hours at 80% is very good 
and above those reported in high income countries. Similarly adherence to PPI and Octreotide 
was above our expectations. Our QIP improved compliance with the delivery of dual therapy 
and adherence to transfusion triggers. Effects on the need for surgery and mortality which are 
in the middle of the ranges of recent reports are difficult to interpret and require multi center 
studies with much larger numbers to prove any effect of guideline adherence. 
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PROTOCOL SYNOPSIS 
 
Title 
 
UGIT bleed: A comparative outcomes study of pre and post-implementation 
of management guidelines in the Acute Care Surgery Unit, Groote Schuur 
Hospital. 
 
 
Study center 
 
Acute Care Surgery Unit, Groote Schuur Hospital, Cape Town, South Africa 
 
Study period 
 
Retrospective historical control: 01-01-2016 to 31-12-2016 
 
Intervention time: Jan 2017 
 
Prospective Cohort: 01-02-2017 to 31-01-2018 
 
 
Objectives 
 
Primary: 
 
 
 
 Efficacy of our intervention at ensuring optimal endoscopic management of UGIT bleed 
specifically looking at the time to endoscopy and modality used to arrest hemorrhage.

 Mortality and bleed related morbidity comparison pre and post implementation

 Adherence to international consensus guideline for blood transfusion outside 
of resuscitation in the presence of UGIT bleed.
 

 
Secondary: 
 
 
 Audit of ACS, GSH emergency endoscopy practice

 Audit of ACS blood transfusion practice for UGIT bleed

 Audit of ACS mortality and morbidity for UGIT bleed

 Audit of re-bleeding and adjuncts to endoscopy used to arrest bleeding.

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 Design
 
 
 
Comparative study between a historical control group vs prospective cohort post 
implementation of a quality improvement intervention. The Management of UGIT at 
GSH guidelines will be strongly implemented as part of the intervention. 
 
 
Methodology 
 
 
Population: 
 
All patients admitted to the ACS unit a documented UGIT bleed over the time period 
will be included. 
 
 
The exclusion criteria include: 
 
 An Upper endoscopy shows no stigmata of a bleed or causes for an upper GIT bleed

 Patients deemed stable enough to discharge by Emergency unit with a suspected 
GI bleed, i.e. Patients not admitted to ACS
 
 
 
 
Intervention: 
 
 
 
We have identified the general surgical registrars, the consultants covering Acute Care Surgery 
and the Medical GI fellows doing endoscopy calls as our target intervention population. The 
Cape metro-west GI bleed protocol and the GSH Upper GIT bleed guidelines are present but not 
actively implemented. The timing of the endoscopy especially after-hours and the treatment 
modality is up to the knowledge and clinical discretion of the team on call. The registrars 
rotating through ACS are in their 2
nd
 or 3
rd
 year training. The endoscopy consultant is either 
the Acute Care Surgery consultant on-call or a medical GIT fellow, both deemed competent by 
the Unit heads. 
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The intervention will include the following: 
 
 
 
1. Dissemination of all relevant protocols and guidelines to the target group via 
email. These are: 
 
 Upper GI bleed protocol for Cape Metro-west as written by Prof. E. Panieri and 
Prof. S. Thomson

 GSH ACS UGIT bleed guidelines as written by Prof. E. Jonas and Dr. S. Rayamajhi

 Data we aim to capture with this study, to ensure they take a relevant 
history and document it inpatient notes


2. A discussion forum with this target group where we will introduce the protocol of this 
study, discuss key points and have a Q&A session to answer their concerns about this 
study. This meeting will ideally be done the beginning of 2017(January) pending the 
results of the DRC. 
 
3. Poster of management algorithm will be put up in the emergency department, 
E23 endoscopy unit and F25 Acute Care ward. 
 
4. With each new group of rotating Acute care registrars (6 registrars at a time, rotate 
3 monthly), we will hold an information session again to re-enforce the guidelines. 
 
 
The aim of the intervention will be to enforce the following: 
 
 Early endoscopy:

1. Unstable hemodynamics – ASAP or within 2hours of arrival. 
 
2. Stable or well resuscitated –suspected variceal bleeds within 12 hours, suspected 
non-variceal bleed with Modified Blatchford Score (MBS) >10 within 6 hours, 
MBS <10 within 24 hours 
 
 Dual therapy for ulcer bleeds

 Blood transfusion to Hemoglobin of 7mg/dl for patients without Ischemic Heart 
Disease, Hb of 9mg/dl for patients with IHD (out of resuscitation).
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Data collected 
We aim to collect the following data. The database has been approved by the Human Research 
 
Ethics Committee of UCT, reference no R034/ 2016. 
 
 
Variable Option Rationale 
   
Hospital number   
   
Demographics  Does the burden of 
  disease correlate with 
  international studies or 
  are our patients younger 
  as is the impression 
Age Numerical  
Gender M/F  
   
Presentation   
Current inpatient Yes / No Is mortality higher in 
  patients that bleed as an 
  inpatient while admitted 
  for other causes and not 
  an UGITB 
Transfer from NSH/MPH/VHW/None Is there mortality and 
  morbidity related to 
  Transfer 
Reason for transfer No afterhours scope/ No Identify pitfalls to address 
 scope adjuncts in secondary hospitals 
First presentation to Time  
hospital   
Presentation after hours Yes / No Is there an increased 
  mortality or morbidity risk 
  Is there an increased 
  delay to endoscopy 
   
Presentation status  To risk stratify into High 
  and low risk (MBS) 
Hemodynamics at Stable / Unstable  
presentation   
Systolic BP   
Heart rate   
Admission Hemoglobin   
(lab)   
 49  
Admission Blood Urea   
Melena History / Confirmed / None  
Hematemesis History / Confirmed / None  
Syncope Yes / No  
Resuscitation Fluids / Blood / Inotropes /  
 None  
   
Risk factors for Peptic  To identify the burden of 
ulcer disease /bleeding  PUD from Smoking and 
  NSAID use in the South 
  African setting 
Smoking Daily / Occasionally /  
 Never  
NSAIDs Occasional / Regular /  
 None  
Aspirin Yes / No  
Aspirin dose Prophylactic / Analgesic  
Previous UGITB Yes / No  
Warfarin Yes / No  
   
Co-morbid diseases (on  To enable risk 
history or active)  stratification according to 
  internationally validated 
  Rockall score 
Ischemic heart disease Yes / No  
Cardiac failure Yes / No  
Chronic renal failure Yes / No  
Liver disease/ failure Yes / No  
Modified Blatchford Score Numerical  
   
Endoscopy findings   
Time to endoscopy In hours  
Scope location GI unit / Theater  
Bleeding evidence on No blood / Fresh blood /  
Scope Old blood  
Scope findings Esophageal varices /  
 Gastric varices / PUD /  
 Mallory Weiss tear /  
 Vascular malformation  
Esophageal varices Active bleed / Not bleeding  
Varices grade Occupy more than half the  
 lumen / Occupy less than  
 half the lumen  
 50   
   
Endoscopy therapy  What is our practice and 
  has our intervention 
  changed it 
Varices therapy Bands / Sengstaken  
 /Sclerotherapy  
Number of Bands   
Variceal adjuncts TIPPS / Surgery  
PUD forrest classification Forrest classification  
Ulcer site Duodenal / Antral or pre-  
 pyloric / Incisura / Gastric  
 Body  
Ulcer endotherapy Injection / Clip / Thermal  
Ulcer dual therapy Yes / No  
Monotherapy reasons Adjuncts unavailable / Identify pitfalls 
 Adjuncts malfunction /  
 Lack of skills  
Bleeding controlled after Yes / No  
endotherapy   
Total no of endoscopy   
Intervention radiology Yes / No  
Surgery Yes / No  
Surgical management Vessel oversewn / distal  
 gastrectomy / total  
 Gastrectomy  
Bleeding stopped after Yes /No  
Surgery or Intervention   
radiology   
Rockall score Numerical  
Child-Pugh score A /B/ C Grade severity of liver 
  disease/ cirrhosis 
   
Blood transfusion practice  Do we follow consensus 
  guidelines for transfusion 
  outside of a resuscitation 
  Scenario 
Blood transfusion Yes / No  
Hemoglobin prior to   
transfusion for low Hb   
only (lab)   
Transfusion purpose Resuscitation / Low Hb  
   
Morbidity   
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Complications Yes / No  
Complication post- Wound / Pulmonary /  
operative Intra-abdominal  
Grade worst complication Clavien Dindo classification  
Complication other   
Death Yes /No  
Death bleeding related Yes / No  
   
Hospital stay   
Length of stay Days  
Length of ICU stay   
 
 
 
 
Data management 
 
Data will be captured using a red cap online form. Only the principal investigators will have 
access to this online database which is password controlled and firewall- protected. The 
excel spreadsheet that is exported from the red cap for analysis will be stored in the 
principal investigators computer which is password controlled. 
 
 
Statistical analysis 
 
 
 
Continuous variables that are normally distributed will be compared using parametric analysis. 
Categorical variables and skewed data will be compared using non-parametric methods. Sample 
size will be determined by the accrual of patients during the study period, which is estimated to 
be approximately 200 patients. This will power the study to 90% to demonstrate a proportional 
difference between the pre and post-intervention cohorts of 20% (p<0.05). 
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Ethics 
 
 
 
Ethics for the database has already been approved. R244/2017 HREC. As discussed with HREC 
for the prospective data collection we will obtain verbal consent from the patients. This will be 
documented in the patient notes. Patients will be informed that their management will not 
alter and we are collecting data for study purposes. 
 
 
Ethics for the study will be obtained from the Faculty of Health Sciences UCT Human 
Research Ethics Committee University of Cape Town. 
 
 
Only the hospital number will be used to identify the patient, no use of names or address is 
necessary. 
 
Publication 
 
 
We aim to publish the study in a peer-reviewed Journal. The South African experience and 
outcomes can be compared to international publications. The efficacy of the intervention 
will be of interest to the Surgical and GIT community at large. 
 
 
 
Budget 
 
The stationery and posters will be financed by the principal investigators. 
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4. ADDENDUM 
 
4.1 Table1: Pre-Endoscopy Rockall Score 
 
For risk of re-bleeding and death After Admission to the Hospital for Acute UGI bleeding 
 
 
 
Variable Score 0 Score 1 Score 2 Score 3 
     
Age (years) < 60 60-79 >80  
     
Comorbidity Nil major  Congestive Renal 
   heart failure, failure, Liver 
   Ischaemic disease, 
   heart disease metastatic 
    cancer 
     
Shock No shock Pulse >100 Systolic BP  
  bpm >100  
     
Bleeding Mallory- All other Malignancy  
source Weiss tear diagnosis:   
  e.g.,   
  esophagitis,   
  gastritis,   
  peptic ulcer   
  disease,   
  varices   
     
Features of None  Adherent clot,  
recent   spurting vessel  
bleeding     
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4.2 Table 2: Modified Glasgow-Blatchford Score (MBS), pre endoscopy 
assessment 
 
 
 
Risk factors Score 
Blood urea (mmol/L)  
>6.5 to <8 2 
>8 to <10 3 
>10 to <25 4 
>25 6 
Hemoglobin (g/dL), for men  
>12.0 to <13.0 1 
>10.0 to <12.0 3 
<10.0 6 
Hemoglobin (g/dL), for women  
>10.0 to <12.0 1 
<10.0 6 
Systolic blood pressure (mmHg)  
100-109 1 
90-99 2 
<90 3 
Pulse rate per minute  
>100 1 
Maximum score 16 
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4.3 Table 3: AIMS65 scoring system 
 
 
AIMS65 Score  
  
Variable Score 
  
Age >65 1 
Systolic BP <90 1 
Altered mental status 1 
Albumin <3g/L 1 
INR >1.5 1 
Maximum score 5 
  
Scores >2 are considered high risk  
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4.4 Table 4: Forrest classification of upper gastrointestinal hemorrhage 
 
 
Stage Description 
Acute hemorrhage  
Forrest IA Active spurting hemorrhage 
Forrest IB Oozing hemorrhage 
Signs of recent hemorrhage  
Forrest IIA None bleeding visible vessel 
Forrest IIB Adherent clot 
Forrest IIC Dark base/ haematin covered 
Lesion  
Lesion without active bleeding  
Forrest III Clean-base ulcer 
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4.5 Table 5: Child-Turcotte-Pugh Classification for Severity of Liver Cirrhosis 
 
 
 
Parameter 1 Point 2 Points 3 
Points    
    
Ascites None Mild-moderate Sever 
Encephalopathy  None Minimal 
Advanced (coma)    
Albumin (g/L) <35 35-28 <28 
Bilirubin (mmol/L) <34 34-50 >50 
INR <1.7 1.7-2.3 >2.3 
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AWARENESS POSTER 
 
UPPER GASTROINTESTINAL BLEEDING QUALITY IMPROVEMENT PROGRAM 
 
 
GSH ACUTE CARE SURGERY AND MEDICAL GIT UNIT  
 
AIM: PROMOTE ADHERENCE TO UGIT BLEEDING GUIDELINE RECOMMENDATIONS  
 
 
WHAT ARE THE GUIDELINE 
 
RECOMMENDATIONS? 
 
 
 
 
ENDOSCOPY TIMING  
 UNSTABLE: ASAP (<2 hours)
 Stable with MBS ≥ 10: <12 hours
 Stable with MBS < 10: <24 hours
 Stable suspected variceal bleed: <12 
 
ENDOTHERAPY 
 
Dual modality for FORREST I and II ulcers  
 
 
 
TRANSFUSION TRIGGER 
 
Active bleed - as necessary until hemostasis 
 
Out of resuscitation (Top up): 
 
 No Ischemic heart disease – Hb ≥ 7.0 g/dL
 Ischemic heart disease – Hb ≥ 9.0 g/dL
 
 
 
REQUIRED INFORMATION  
 
 
 
MODIFIED BLATCHFORD SCORE (MBS) 
 
Blood urea (mmol/L)  
     
 ≥6.5 <8.0 2  
    
 ≥8.0 <10 3  
    
 ≥10.0 <25 4  
     
 ≥25  6  
    
 Hemoglobin (g/dL) for men   
    
 ≥12.0 <13.0 1  
    
 ≥10.0 <12.0 3  
    
 <10.0  6  
    
 Hemoglobin (g/dL) for women   
     
   1  
 ≥10.0 <12.0   
<10.0  6  
    
 Systolic blood pressure (mmHg)   
    
100-109 1  
   
 90-99 2  
     
<90  3  
     
  Pulse rate per minute   
     
>100  1  
      
 
 
 
 
Data will be prospectively collected for a year from February 2017 
 
For the comparative QIP study (HREC 244/2017) 
 
Principal investigator: Dr Ismail Aborkis, Department of General Surgery, GSH 
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